Akers Biosciences Allowed US Patent for Akers Wellness(TM) Tests Cartridge
February 16 2017 - 7:00AM
Marketwired
Akers Biosciences Allowed US Patent for Akers Wellness(TM) Tests
Cartridge
THOROFARE, NJ-(Marketwired - Feb 16, 2017) - Akers Biosciences,
Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company" or "Akers Bio"), a
developer of rapid health information technologies, announces that
the United States Patent and Trademark Office has allowed a patent
covering Akers Bio's proprietary cartridge for the optical scanning
device utilized in the Company's BreathScan Lync technology.
BreathScan Lync is the new bluetooth-enabled reading device from
Akers Wellness which enables users to track the results of Akers
Wellness breath-based tests via their mobile device.
The patent covers the unique design of the disposable cartridge
which contains the reagent for the detection of wellness markers.
The reagent contained within is analyzed using optical scanning
technology after contact with the user's exhaled breath sample and
produces a quantitative result through the Akers Wellness app on
the user's smartphone or tablet. Included in the patent are the
unique form factor, optical lens and read elements and the unique
'U' shaped airflow pathway.
Akers Wellness breath tests, such as BreathScan OxiChek and
BreathScan KetoChek, are designed to help promote, track and/or
encourage choices related to general health and wellbeing; or to
support weight loss.
Update on Commercialization of Akers Wellness Tests
OxiChek is now fully commercialized and selling through the
Company's distributor, Aero-Med, to anti-aging, functional and
integrative health and wellness treatment practitioners in the
US.
OxiChek is the first disposable breath test to rapidly determine
levels of oxidative stress in the body by measuring the levels of
certain abundant free radicals. Frequent use of OxiChek may help
health practitioners to monitor and adjust their clients' regimen
of nutritional supplementation in order to manage oxidative stress
- an indicator of the overall health and wellbeing of a person.
The Company is ramping up marketing initiatives of OxiChek to
professionals through enhanced e-commerce and social media
platforms as well as through participation in large trade shows
targeting naturopaths, wellness coaches, anti-aging practitioners,
nutritionists and chiropractors.
In addition to targeting professionals, Akers Wellness intends
to start marketing OxiChek through direct-to-consumer channels
during 2017. This will include a television marketing campaign
through the popular Balancing Act national television show on the
Lifetime network. Balancing Act is America's premier morning show
that introduces positive solutions to busy, on-the-go modern women.
Akers Wellness has completed filming of the program, which will be
aired multiple times on Lifetime during Q2 2017 and syndicated to
approximately 200 affiliates. This marketing initiative is
targeting women aged 25-45 and will potentially reach approximately
98 million households and thousands of online viewers.
Akers Wellness is in discussions with potential distributors for
the KetoChek test which rapidly determines if the subject is in the
optimal fat-burning state for weight loss, known as ketosis.
Achieving a state of ketosis - as indicated by the measure of
breath ketones - is a goal of many individuals following low
carbohydrate diets. KetoChek is a simple, non-invasive test to
identify, track and quantitatively monitor breath ketones for
individuals interested in maximizing weight loss.
The Company looks forward to providing further updates on the
commercialization progress of Akers Wellness tests during 2017.
John J. Gormally, Chief Executive Officer of Akers Bio,
commented:
"We believe Akers Bio's technology for rapidly analyzing
biomarkers in breath condensate is ideally suited for tests in the
expansive US health and wellness market. I am pleased that this
latest patent has been allowed as it is essential that we have
robust protection over our valuable intellectual property.
"OxiChek is the first fully commercialized Akers Wellness test
in which this cartridge is applied. We are pleased that initial
sales of this test are being recorded and excited about the scope
for ramping up sales through national television marketing
initiatives and major tradeshow participation. I look forward to
reporting further progress on the Akers Wellness product line
during the course of 2017."
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target," "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information: Akers Biosciences, Inc. John J. Gormally,
Chief Executive Officer Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698 Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber Tel. +1 917 445 6207 Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker) Adrian Hargrave / Scott
Mathieson (Corporate Finance) Steve Norcross (Broking) Tel. +44
(0)20 7220 0500 Vigo Communications (Global Public Relations) Ben
Simons / Fiona Henson Tel. +44 (0)20 7830 9704 Email:
akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Sep 2023 to Sep 2024